| 0 (0%) | 11-11 15:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 85.04 | 1-year : | 99.32 |
| Resists | First : | 72.8 | Second : | 85.04 |
| Pivot price | 65.59 |
|||
| Supports | First : | 63.5 |
Second : | 57.75 |
| MAs | MA(5) : | 67.48  |
MA(20) : | 64.65 |
| MA(100) : | 53.86 |
MA(250) : | 52.9 |
|
| MACD | MACD : | 2.6 |
Signal : | 2.7 |
| %K %D | K(14,3) : | 44.1 |
D(3) : | 48.1 |
| RSI | RSI(14): 67.2 |
|||
| 52-week | High : | 72.8 | Low : | 38.81 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EXAS ] has closed below upper band by 25.0%. Bollinger Bands are 14.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 68.47 - 68.81 | 68.81 - 69.15 |
| Low: | 65.41 - 65.76 | 65.76 - 66.11 |
| Close: | 66.03 - 66.57 | 66.57 - 67.12 |
Tue, 11 Nov 2025
EXAS: Piper Sandler Maintains Rating, Raises Price Target to $80 | EXAS Stock News - GuruFocus
Mon, 10 Nov 2025
Does Oncoguard Liver’s Strong Data Transform the Growth Narrative for Exact Sciences (EXAS)? - simplywall.st
Mon, 10 Nov 2025
Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Mon, 10 Nov 2025
Exact Sciences (NASDAQ: EXAS) HSR Expiration for Exclusive Freenome CRC License - Stock Titan
Mon, 10 Nov 2025
Is EXAS stock supported by strong fundamentals - 2025 Earnings Surprises & Daily Entry Point Trade Alerts - newser.com
Thu, 06 Nov 2025
Baranick, Exact Sciences EVP, sells $200k in EXAS stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 189 (M) |
| Shares Float | 187 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 95.5 (%) |
| Shares Short | 7,970 (K) |
| Shares Short P.Month | 8,090 (K) |
| EPS | -5.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.05 |
| Profit Margin | -34.2 % |
| Operating Margin | 0.3 % |
| Return on Assets (ttm) | -1.4 % |
| Return on Equity (ttm) | -35.6 % |
| Qtrly Rev. Growth | 16 % |
| Gross Profit (p.s.) | 10.82 |
| Sales Per Share | 15.52 |
| EBITDA (p.s.) | 0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 306 (M) |
| Levered Free Cash Flow | 140 (M) |
| PE Ratio | -12.45 |
| PEG Ratio | 0 |
| Price to Book value | 5.19 |
| Price to Sales | 4.36 |
| Price to Cash Flow | 42.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|